This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
UnitedHealth (UNH) Q3 Earnings Likely to Beat: Here's Why?
by Zacks Equity Research
UnitedHealth's (UNH) third-quarter earnings are expected to benefit from strong contribution from both its segments along earnings accretion from disciplined capital management.
Molina Healthcare Appoints CEO: Will New Leadership Help?
by Zacks Equity Research
Molina Healthcare (MOH) appoints new CEO in an attempt to regain its lost glory.
WellCare Health Grows on Revenues, Debt Level Hurts
by Zacks Equity Research
Wellcare Health's (WCG) revenues continue to grow on the back of several organic and inorganic growth strategies. However, rising level of debt and expenses keep draining the bottom line.
Humana Partners With Community Care, Improves Healthcare
by Zacks Equity Research
Humana (HUM) builds strategic alliances in order to expand its geographical presence and ensure premium quality of healthcare by strengthening its value proposition.
Anthem Grows on Membership, Public Exchange Woes Hurt
by Zacks Equity Research
Although Anthem's (ANTM) revenue base continues to strengthen on the back of growing membership. Losses incurred in the public exchange business bother.
Public Exchange Woes Hit Health Insurers: Stocks in Focus
by Zacks Equity Research
The U.S private health insurers have been incurring mounting losses from the health insurance marketplace. This has led many of them to pull back participation, worsening the scenario for underprivileged Americans.
3 Value Stocks in Health Insurance to Bet On
by Zacks Equity Research
The Health Insurance industry gains from growing government business, benefits of ACA, business diversification and profit-boosting medical plans despite regulatory hurdles
Humana (HUM) Up 6.4% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Humana (HUM) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Humana (HUM) Hits 52-Week High on Solid Q2, Raised Outlook
by Zacks Equity Research
Humana's (HUM) shares have been favored by its strong earnings performance, guidance raise and completion of accelerated share buyback.
Wellcare Health's (WCG) Inorganic Growth Boosts Revenues
by Zacks Equity Research
Wellcare Health's (WCG) solid top line grows on strategic acquisitions and alliances. Its strong financial health also bodes well for long-term growth.
Aetna's (AET) $1 Billion Notes Due 2047 Rated By A.M Best
by Zacks Equity Research
Rating Giant A.M Bests assigned a Long-Term Issue Credit Rating of "bbb" to Aetna's (AET) $1 billion, 3.875% senior notes due to mature on Aug 15, 2047.
Envision Healthcare (EVHC) Q2 Earnings Beat, '17 View Cut
by Zacks Equity Research
Envision Healthcare's (EVHC) strong second-quarter earnings were driven by revenue growth in the Physician Services segment, partly offset by an increase in operating expenses.
Select Medical (SEM) Q2 Earnings Top Estimates, Revises View
by Zacks Equity Research
Select Medical's (SEM) solid Q2 results were driven by the strong performance of all segments.
Tenet Healthcare's (THC) Q2 Loss In Line with Estimates
by Zacks Equity Research
Tenet Healthcare (THC) incurred net loss in second-quarter 2017 owing to lower revenue generation.
Cigna (CI) Earnings Beat in Q2, Guidance Raised, Shares Gain
by Zacks Equity Research
Higher revenues, strength in its Global HealthCare segment and membership growth drive an earnings beat at Cigna (CI) in Q2.
The Ensign Group (ENSG) Q2 Earnings Miss Estimates, Up Y/Y
by Zacks Equity Research
The Ensign Group's (ENSG) second-quarter earnings missed expectations owing to higher expenses.
Aetna (AET) Tops Q2 Earnings, Revenues, Raises 2017 Guidance
by Zacks Equity Research
Aetna's (AET) strong second-quarter 2017 results were largely driven by improved expense ratio.
Teladoc (TDOC) Q2 Loss Wider than Expected, Revenues Up Y/Y
by Zacks Equity Research
Teladoc's (TDOC) second-quarter loss was wider than expected due to higher expenses.
Molina Healthcare (MOH) Incurs Loss in Q2, Revenues Beat
by Zacks Equity Research
Molina Healthcare (MOH) incurred loss in the second-quarter 2017 owing to higher medical care costs.
Humana (HUM) Beats Earnings Estimates, Lags Revenues in Q2
by Zacks Equity Research
Humana's (HUM) second-quarter earnings were driven by higher revenues.
Humana's (HUM) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Humana surpassed our earnings estimate. Our consensus called for EPS of $3.08, and the company reported EPS of $3.49.
Healthcare Q2 Earnings Due on Aug 2: HUM, PRXL, MOH, TDOC
by Zacks Equity Research
The Medical sector is likely to benefit from inorganic growth, product launches, technology upgrades. However, regulatory hassles might offset its growth potential.
What's in the Cards for Humana (HUM) this Earnings Season?
by Zacks Equity Research
Humana's (HUM) second-quarter earnings are likely to be driven by Medicare membership growth.
What to Expect from Anthem (ANTM) this Earnings Season?
by Zacks Equity Research
Anthem's (ANTM) second-quarter earnings are likely to be supported by robust medical enrollment. However, rising level of SG&A expenses might put pressure on the bottom line.
Centene (CNC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Centene's (CNC) second-quarter earnings are likely to be driven by Health Net buyout. However, surging level of SG&A expenses might put pressure on the bottom line.